{"id":408066,"date":"2019-08-14T00:00:00","date_gmt":"2019-08-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0001-2019-biopharma-breast-cancer-unmet-need-metastatic-triple-negative-breast-cancer-us-eu-2019\/"},"modified":"2026-05-05T11:22:35","modified_gmt":"2026-05-05T11:22:35","slug":"unneon0001-2019-biopharma-breast-cancer-unmet-need-metastatic-triple-negative-breast-cancer-us-eu-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0001-2019-biopharma-breast-cancer-unmet-need-metastatic-triple-negative-breast-cancer-us-eu-2019\/","title":{"rendered":"Breast Cancer | Unmet Need | Metastatic Triple-Negative Breast Cancer | US\/EU | 2019"},"content":{"rendered":"<p>Triple-negative breast cancer (TNBC) is a patient population with high unmet need\u00a0given the poor outcomes associated with current treatment options and the historic lack of targeted therapies available. The treatment landscape has evolved in recent years\u00a0with the approval of PARP inhibitors Lynparza and Talzenna for patients with germline <em>BRCA<\/em> mutations and Tecentriq plus Abraxane for PD-L1-positive patients. Despite the availability of new therapies, significant clinical and commercial opportunity remains for the development of targeted and\/or immune-based therapies to improve survival outcomes. Our unmet need module analyzes the key drivers of prescribing and assesses how emerging therapies may capitalize on these opportunities.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>\u00a0What are the key drivers that are most likely to influence treatment uptake for advanced \/\u00a0metastatic TNBC?<\/li>\n<li>\u00a0How do current therapies perform on key treatment drivers and goals for advanced \/\u00a0metastatic TNBC?<\/li>\n<li>What are the prevailing areas of unmet need and opportunities in advanced \/\u00a0metastatic TNBC?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical therapy in newly diagnosed advanced \/\u00a0metastatic TNBC?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60\u00a0U.S. and 30\u00a0European medical oncologists\u00a0fielded in May\u00a02019.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0Roche \/ Genentech, Celgene, AstraZeneca, Pfizer, Eisai.<\/p>\n<p><strong>Key drugs:<\/strong> Tecentriq, Abraxane, Lynparza, Talzenna, Halaven, Avastin.<\/p>\n","protected":false},"template":"","class_list":["post-408066","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/408066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/408066\/revisions"}],"predecessor-version":[{"id":408397,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/408066\/revisions\/408397"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=408066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}